Detalhe da pesquisa
1.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469182
2.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 827-836, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047804
3.
Extracting Value from Industrial Alarms and Events: A Data-Driven Approach Based on Exploratory Data Analysis.
Sensors (Basel)
; 19(12)2019 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31226811
4.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Nat Med
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38745009
5.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
J Clin Oncol
; 41(4): 816-825, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379002
6.
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Cancer Sci
; 102(2): 478-83, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21143703
7.
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Oncology
; 81(2): 65-72, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21968463
8.
[Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU®)].
Nihon Yakurigaku Zasshi
; 156(1): 47-51, 2021.
Artigo
em Japonês
| MEDLINE | ID: mdl-33390481
9.
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Cancer Discov
; 10(5): 688-701, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213540
10.
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.
Cancer Chemother Pharmacol
; 73(3): 577-83, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24452393
11.
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 69(3): 753-61, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22020317
12.
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
J Thorac Oncol
; 6(8): 1400-6, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21673602
13.
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer.
J Thorac Oncol
; 6(4): 790-5, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21325974